Want to see IN:KREBSBIO full AI Analyst Report?

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Price & Analysis

0 Followers

KREBSBIO Stock Chart & Stats

₹71.00

-₹2.80(-2.89%)

At close: Jan 08 4:00 PM EST

₹71.00

-₹2.80(-2.89%)

Day’s Range― - ―

52-Week Range₹38.52 - ₹77.85

Previous CloseN/A

Volume3.29K

Average Volume (3M)3.40K

Market Cap

₹1.14B

Enterprise Value₹3.11B

Total Cash (Recent Filing)₹1.29M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.54

Shares Outstanding21,560,587

10 Day Avg. Volume1,013

30 Day Avg. Volume3,401

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)-0.53

Price to Sales (P/S)3.61

P/FCF Ratio-7.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Gross Margin RecoveryGross margin turned positive in 2025–2026 after being negative in earlier periods, indicating some improvement in product-level economics. If sustained, this gives the company a better base to absorb operating costs and rebuild profitability, although the pack says it has not yet produced overall profits.

EPS GrowthReported EPS growth of 47.98% is a favorable earnings trend within the available data. However, because the company remains loss-making, this improvement should be viewed as a potential operating inflection rather than proof of durable earnings power; continued execution is needed.

Chemical Manufacturing OperationsThe company has an operating base in chemical manufacturing, with 142 employees and revenue generated by producing and selling chemical products. This provides an identifiable commercial activity and production platform on which improved utilization, pricing, and cost control could be pursued over time.

Bears Say

Persistent Losses And Revenue DeclinePersistent EBIT and net losses, combined with another revenue decline in 2026, indicate that the business has not yet converted operations into sustainable earnings. Continued contraction can reduce scale benefits, weaken cost absorption, and make recovery dependent on a material improvement in demand or margins.

Negative Equity And Heavy LeverageNegative shareholders’ equity across every reported year and heavy debt relative to the asset base materially weaken financial resilience. This structure can restrict investment capacity, increase refinancing and solvency pressure, and leave less flexibility to withstand continued operating losses or fund a recovery.

Persistent Cash BurnNegative free cash flow in every reported year shows that the company has not generated enough cash to fund its activities internally. Repeated operating cash deficits can increase reliance on external financing and compound balance-sheet stress, even though free cash flow improved from the prior year.

Krebs Biochemicals & Industries Ltd. News

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) has shared an update. Krebs Biochemicals & Industries Ltd. announced...

9M ago

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) just unveiled an update. Krebs Biochemicals & Industries Ltd. has...

10M ago

KREBSBIO FAQ

What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?

Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹77.85 in the past 12 months.

What is Krebs Biochemicals & Industries Ltd.’s market cap?

Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.14B.

When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?

Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is Oct 29, 2026 which is in 3 days.

How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?

Krebs Biochemicals & Industries Ltd. released its earnings results on Aug 07, 2026. The company reported -₹1.152 earnings per share for the quarter.

Is Krebs Biochemicals & Industries Ltd. overvalued?

According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Krebs Biochemicals & Industries Ltd. pay dividends?

Krebs Biochemicals & Industries Ltd. does not currently pay dividends.

What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?

Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.

What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?

Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.152 in its last earnings report. Following the earnings report the stock price went up 7.029%.

Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?

Currently, no hedge funds are holding shares in IN:KREBSBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Krebs Biochemicals & Industries Ltd.

Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.